Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to $162.2 million.

  • BIO-TECHNE's Cash & Equivalents fell 22.70% to $145.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year decrease of 22.70%. This contributed to the annual value of $162.2 million for FY2025, which is 6.85% up from last year.
  • As of FY2025, BIO-TECHNE's Cash & Equivalents stood at $162.2 million, which was up 6.85% from $151.8 million recorded in FY2024.
  • In the past 5 years, BIO-TECHNE's Cash & Equivalents ranged from a high of $199.1 million in FY2021 and a low of $151.8 million during FY2024.
  • In the last 3 years, BIO-TECHNE's Cash & Equivalents had a median value of $162.2 million in 2025 and averaged $164.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 35.78% in 2021, then dropped by 15.94% in 2024.
  • BIO-TECHNE's Cash & Equivalents (Yearly) stood at $199.1 million in 2021, then declined by 13.32% to $172.6 million in 2022, then rose by 4.64% to $180.6 million in 2023, then dropped by 15.94% to $151.8 million in 2024, then increased by 6.85% to $162.2 million in 2025.